AI driven Leverage Lantern Pharma's RADR AI platform and large-scale genomic data capabilities to position offerings around AI-powered drug discovery services, patient stratification solutions, and predictive biomarkers as value-add for pharma partners seeking faster, more accurate oncology programs.

Pediatric CNS focus Target opportunities related to STAR-001 and pediatric CNS tumor programs, including potential collaborations or services around IND management, Phase 1 trial support, and regulatory strategy tailored to pediatric oncology.

Global expansion Capitalizing on their new AI Center of Excellence in Bengaluru, India, propose partnerships for regional pilot projects, data processing outsourcing, and cost-effective, rapid iteration of drug discovery workflows for global sponsors.

Multi-agent platform Position ZetaSwarm and Large Quantitative Model capabilities to pharma clients seeking scalable AI-driven reasoning across multiple agents, enabling parallel hypothesis testing, accelerated hit-to-lead cycles, and smarter trial design.

Clinical stage momentum Explore opportunities to supply precision oncology services such as patient stratification, mechanism-of-action studies, and companion diagnostics development to sponsors advancing oncology assets in mid- to late-stage pipelines, leveraging Lantern’s track record in coordinating AI for oncology trials.